Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)

electrophoresis
line of therapy
measurable disease
lenalidomide
bortezomib
  • 57 views
  • 24 Jan, 2022
  • 18 locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085

monoclonal antibodies
immunotherapeutic agent
cell transplantation
ixazomib
thalidomide
  • 30 views
  • 21 Jan, 2022
  • 22 locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085

cell transplantation
carfilzomib
measurable disease
lenalidomide
refractory multiple myeloma
  • 0 views
  • 22 Jan, 2022
  • 8 locations
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute …

dexamethasone
measurable disease
lenalidomide
pomalidomide
refractory multiple myeloma
  • 33 views
  • 22 Jan, 2022
  • 24 locations
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival

dexamethasone
bone marrow plasma cells
bone marrow procedure
smoldering myeloma
lenalidomide
  • 12 views
  • 17 Jan, 2022
  • 154 locations
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

human chorionic gonadotropin
measurable disease
lenalidomide
refractory multiple myeloma
bortezomib
  • 0 views
  • 14 Jan, 2022
  • 29 locations
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously

cell transplantation
progressive disease
corticosteroids
refractory multiple myeloma
daratumumab
  • 28 views
  • 15 Jan, 2022
  • 163 locations
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (ITHACA)

multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival

dexamethasone
neutrophil count
bone marrow procedure
lenalidomide
  • 10 views
  • 23 Jan, 2022
  • 92 locations
A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

measurable disease
multiple myeloma
  • 0 views
  • 12 Jan, 2022
  • 18 locations
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

measurable disease
multiple myeloma
  • 0 views
  • 09 Jan, 2022
  • 82 locations